9
04, 2019
19
03, 2019
18
03, 2019
11
03, 2019
4
03, 2019
26
02, 2019
24
02, 2019
22
02, 2019
14
02, 2019
Lorenza Rimassa et al., Phase 2 study of tivantinib and cetuximab in KRAS wild-type metastatic colorectal cancer patients with acquired resistance to EGFR inhibitors and emergence of MET overexpression: lesson learned for future trials with EGFR/MET dual inhibition
Diatech Pharmacogenetics2020-01-22T12:34:32+01:00
5
02, 2019